Lupin Share News - Latest Updates, Live News & More

More news about Lupin

Lupin enters China market with Oseltamivir approval

Lupin has received approval from China's National Medical Products Administration for its Oseltamivir Phosphate Oral Suspension, marking its first product entry into the Chinese market. The approval was granted for an Abbreviated New Drug Application in partnership with Yabao Pharmaceuticals. This milestone represents a significant step in Lupin's global expansion strategy.

21May 26

Lupin Records Rs. 17.19 Crore Block Trade on NSE at Rs. 2289.30 Per Share

Lupin recorded a block trade on the NSE involving approximately 75,090 shares executed at Rs. 2289.30 per share, with a total transaction value of Rs. 17.19 crores. Such large-volume trades are typically carried out by institutional investors or high-net-worth participants outside the regular order book to minimize price impact.

20May 26

Lupin Debuts in Dow Jones Best-in-Class Indices 2026

Lupin Limited debuted in the Dow Jones Best-in-Class (DJBIC) Indices 2026, featuring in both the World and Emerging Markets indices based on its strong ESG performance. This inclusion follows the company's ranking among the top 1% globally in the S&P Global Corporate Sustainability Assessment (CSA) 2025, where it achieved an industry-leading score of 91/100. The indices track the top 10% of the largest companies in the S&P Global Broad Market Index by sustainability performance.

19May 26

Lupin Inaugurates Atharv Ability Neuro-Rehabilitation Center in Delhi, Expanding Specialized Care in North India

Lupin Limited launched its third Atharv Ability neuro-rehabilitation center in Naraina Vihar, Delhi on May 15, 2026, under Regulation 30 disclosure. The facility offers advanced care including end-effector robotics, AI-based balance systems, and multidisciplinary therapies for neurological conditions such as stroke, Parkinson's disease, and cerebral palsy, expanding specialized care access across North India.

19May 26

Lupin Receives Tentative US FDA Approval for Refevenacin Inhalation Solution

Lupin has obtained a tentative approval from the US FDA for Refevenacin Inhalation Solution. The tentative approval indicates the product has met all regulatory requirements set by the US FDA. This development highlights Lupin's continued efforts to expand its respiratory product portfolio in the United States.

14May 26

Lupin Receives U.S. FDA Approval for Famotidine Injection

Lupin has obtained U.S. FDA approval for Famotidine Injection, adding to its injectable generics portfolio in the United States. Famotidine is a histamine-2 blocker used for treating conditions associated with excess stomach acid. This regulatory milestone highlights Lupin's continued focus on expanding its presence in the U.S. pharmaceutical market through new product approvals.

11May 26

Lupin Q4 FY26 Beats Estimates; CLSA, Nomura & Morgan Stanley Bullish on Strong US-Led Performance

Lupin's Q4 FY26 results beat estimates with consolidated net profit rising to ₹14.6 billion and EBITDA margin expanding to 33.6%. CLSA maintained Outperform at ₹2,690, Nomura maintained Buy at ₹2,580, and Morgan Stanley maintained Equal-weight at ₹2,386, all citing strong US-led performance. Management guided for high-single to low-double-digit FY27 revenue growth and 25% EBITDA margin, while flagging potential US margin headwinds amid competition in key products.

11May 26

Lupin Targets $1B+ US Revenue and 25% EBITDA Margins for FY27 Amid Pipeline Expansion

Lupin has outlined its FY27 financial roadmap, projecting US revenue above $1 billion despite anticipated high single-digit to low double-digit declines from competition on Tolvaptan and Mirabegron. The company targets strong single-digit revenue growth, ~25% EBITDA margins, a 25-26% effective tax rate, and over 20 product launches, while planning key FY28 launches including Ranibizumab and Dulera. Its longer-term strategy focuses on complex generics and biosimilars through 2028–2031.

08May 26

Lupin Limited Recommends Deloitte Haskins & Sells as Statutory Auditors for a Five-Year Term

Lupin Limited's Board of Directors, at its meeting on May 07, 2026, recommended the appointment of Deloitte Haskins & Sells Chartered Accountants LLP (Firm Registration No. 117364W/W100739) as Statutory Auditors for a first term of five consecutive years, from the conclusion of the Forty-Fourth AGM to the Forty-Ninth AGM. The recommendation follows the completion of the second consecutive five-year term of the existing auditors, B S R & Co. LLP Chartered Accountants. The appointment remains subject to approval by the company's members at the ensuing AGM. The intimation was made in compliance with Regulation 30 of the SEBI Listing Regulations.

05May 26

Lupin Limited Announces Special Window for Transfer and Dematerialization of Physical Shares

Lupin Limited has opened a special window from February 05, 2026 to February 04, 2027 for the transfer and dematerialization of physical securities sold or purchased prior to April 01, 2019, in compliance with SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026 dated January 30, 2026. Transfer requests previously rejected or returned due to document deficiencies must be re-lodged with the RTA, MUFG Intime India Pvt. Ltd., within the stipulated window period. Upon successful transfer, shares will be credited in demat mode only and will be subject to a one-year lock-in period from the date of registration. Cases involving disputes between transferor and transferee, or securities already transferred to the IEPF, are excluded from this special window.

05May 26

Lupin Receives U.S. FDA Approval for Glycerol Phenylbutyrate Oral Liquid, Generic of Ravicti®

Lupin Limited received U.S. FDA approval on May 5, 2026, for its ANDA for Glycerol Phenylbutyrate Oral Liquid, 1.1 grams per mL, a generic equivalent of Ravicti® Oral Liquid by Horizon Therapeutics U.S. Holding LLC. The product is indicated for the chronic management of patients with urea cycle disorders that cannot be controlled by dietary protein restriction and/or amino acid supplementation alone. The RLD Ravicti® recorded product sales of USD 337 million for the year ended December 2025, as per IQVIA MAT DEC 2025 data.

04May 26

Lupin Allots 36,752 Equity Shares Under ESOP, Paid-Up Capital Rises to ₹91,44,31,726

Lupin Limited, on May 4, 2026, allotted 36,752 fully paid-up equity shares of ₹2/- each under its Employee Stock Option plans, following the exercise of vested options by employees and subsidiary staff. The allotment was approved by the company's Operations and Finance Committee at its meeting on the same date. As a result, the company's issued and paid-up share capital has increased to ₹91,44,31,726, comprising 45,72,15,863 equity shares of ₹2/- each. The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

25Apr 26

Lupin Limited Announces Q4 FY26 Earnings Call Scheduled for May 8, 2026

Lupin Limited has officially announced its Q4 FY26 earnings call scheduled for May 8, 2026 at 16:00 hrs IST via Zoom platform. The announcement was made in compliance with SEBI Listing Regulations, with proper notifications sent to NSE and BSE exchanges, and includes comprehensive stakeholder access arrangements.

23Apr 26

Lupin Limited Announces Board Meeting on May 7, 2026 for Q4FY26 Financial Results

Lupin Limited has scheduled its Board of Directors meeting for May 7, 2026, to approve audited financial results for Q4FY26 and consider dividend recommendations. The company has implemented a trading window closure from April 1, 2026, until May 10, 2026, affecting promoters, directors, and other designated personnel in compliance with SEBI regulations.

22Apr 26

Lupin Launches FDA-Approved Diabetes Drug in US Market with Multiple Dosage Strengths

Lupin Limited has officially launched Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States following FDA approval of its ANDA application. The diabetes treatment medication is available in four dosage strengths and is bioequivalent to AstraZeneca's Xigduo XR, representing a significant expansion of Lupin's pharmaceutical portfolio in the American market.

20Apr 26

Lupin Receives USFDA Form 483 With Three Observations For Somerset Facility

Lupin has received a Form 483 from the USFDA containing three observations for its Somerset, New Jersey manufacturing facility following an inspection conducted from April 13-17, 2026. The pharmaceutical company disclosed this regulatory development to stock exchanges and committed to addressing the compliance observations within the required timeframe while maintaining cGMP standards.

17Apr 26

Lupin Records Rs. 15.34 Crore Block Trade on NSE at Rs. 2310.70 Per Share

Lupin Ltd. executed a major block trade on NSE worth Rs. 15.34 crores involving approximately 66,399 shares at Rs. 2310.70 per share. The transaction represents significant institutional activity and demonstrates substantial market interest in the pharmaceutical company's stock.

17Apr 26

Lupin's US Subsidiary Settles Antitrust Dispute with Humana for $30 Million

Lupin Limited disclosed that its wholly-owned US subsidiary Lupin Pharmaceuticals Inc. has reached a $30 million settlement with Humana Inc. in antitrust litigation related to alleged anticompetitive behavior in generic pharmaceuticals. The subsidiary denies all allegations but chose to settle to avoid litigation costs and uncertainties, with the settlement amount already accounted for in previous financial results.

11Apr 26

Lupin Launches Dapagliflozin Tablets in US Following FDA Approval

Lupin Limited has successfully launched Dapagliflozin Tablets in 5mg and 10mg strengths in the United States following FDA approval of its Abbreviated New Drug Application. The tablets are bioequivalent to Farxiga® and represent another milestone in Lupin's diabetes care portfolio expansion in the American pharmaceutical market.

09Apr 26

Lupin Limited Grants 6,495 Stock Options to Employees Under ESOP Plan

Lupin Limited granted 6,495 stock options to employees under its 2011 ESOP plan, approved by the Nomination and Remuneration Committee on April 09, 2026. The options carry an exercise price of ₹2.00 each, with a structured vesting schedule of 25% annually over four years starting one year from the grant date. Each option entitles holders to subscribe to one equity share upon vesting.

08Apr 26

Biocon Gets FDA Nod for Dapagliflozin Tablets in 5mg and 10mg Strengths

Biocon Pharma Limited has secured US FDA approval for Dapagliflozin Tablets in 5mg and 10mg strengths, indicated for type 2 diabetes treatment and reducing heart failure hospitalization risk. This regulatory milestone enhances Biocon's comprehensive diabetes portfolio and will be manufactured at FDA-approved facilities.

07Apr 26

Lupin Limited Receives Great Place To Work® Certification™ for 2026-27

Lupin Limited has received the Great Place To Work® certification for 2026-27, becoming one of select pharmaceutical companies to achieve this global workplace excellence recognition. The certification was earned through a comprehensive evaluation with 85% employee participation across all subsidiaries and geographies. In FY25, Lupin invested INR 40 billion in employee benefits and provided 1,253,456 hours of employee training for its workforce of over 24,000 professionals globally.

07Apr 26

Lupin Limited Submits Quarterly Compliance Certificate for Q4 FY26

Lupin Limited has submitted its quarterly compliance certificate for Q4 FY26 pursuant to SEBI Regulation 74(5), confirming proper handling of dematerialized securities. The certificate was issued by registrar MUFG Intime India Private Limited and submitted to stock exchanges on April 6, 2026. This represents standard regulatory compliance ensuring transparency in share transfer processes for the quarter ended March 31, 2026.

02Apr 26

Lupin Completes VISUfarma Acquisition, Expands Eye Care Portfolio to 60+ Products

Lupin Limited successfully completed its strategic acquisition of VISUfarma B.V., a European specialty pharmaceutical company, through its Netherlands subsidiary Nanomi B.V. The transaction adds over 60 branded eye care products spanning dry eye, glaucoma, and retinal health segments, while bringing €53 million in revenue and strengthening Lupin's commercial footprint across key European markets including Italy, UK, Spain, Germany, and France.

02Apr 26

Lupin Unit Plans 43.38% Acquisition in Philippines for USD 39.6 Million

Lupin Limited announced its subsidiary Nanomi B.V. will acquire 43.38% stake in Multicare Pharmaceuticals Philippines for up to USD 39.6 million, aiming for complete ownership by May 2026. The acquisition will increase Nanomi's shareholding from 56.28% to 99.66% in the Philippines-based pharmaceutical trading and distribution company.

01Apr 26

Lupin Ltd Records Major Block Trade Worth Rs. 236.53 Crores on NSE

Lupin Ltd recorded a major block trade on NSE involving 1,031,642 shares worth Rs. 236.53 crores at Rs. 2292.80 per share. The transaction highlights significant institutional activity and demonstrates strong liquidity in the pharmaceutical company's equity.

01Apr 26

Lupin Receives Tentative Approval from U.S. FDA for Sugammadex Injection

Lupin Limited has received tentative approval from the U.S. FDA for its Sugammadex Injection in 200 mg/2 mL and 500 mg/5 mL dosage strengths. The product is bioequivalent to Merck's Bridion Injection and is indicated for reversing neuromuscular blockade in adults and pediatric patients aged 2 years and older during surgical procedures.

30Mar 26

Lupin's Philippines Unit Executes Share Buyback, Increases Nanomi's Stake to 56.28%

Lupin's Philippines subsidiary Multicare Pharmaceuticals executed a strategic share buyback of 2.8 million shares, automatically increasing Nanomi's ownership from 51% to 56.28%. The transaction utilized MPPI's retained earnings and was properly disclosed under SEBI regulations, with the company reporting PHP 2,096.60 million in turnover and PHP 1,265.50 million net worth.

25Mar 26

Lupin Gets Tentative U.S. FDA Approval For Pitolisant Tablets 4.45mg And 17.8mg

Lupin Limited has secured tentative approval from the U.S. FDA for its Pitolisant Tablets in two strengths (4.45mg and 17.8mg), which are bioequivalent to the reference drug Wakix®. The tablets will be manufactured at the company's Nagpur facility, strengthening Lupin's presence in the central nervous system therapy segment and expanding its generic pharmaceutical portfolio.

24Mar 26

Lupin Allots 135,892 Equity Shares Under Employee Stock Option Plan

Lupin Limited allotted 135,892 equity shares under its ESOP on March 24, 2026, to employees of the company and its subsidiaries. The shares, with a face value of ₹2/- each, were issued following the exercise of vested stock options. This allotment increased Lupin's paid-up share capital to ₹91,43,58,222, comprising 45,71,79,111 equity shares. The decision was approved by the Operations and Finance Committee and disclosed to stock exchanges in compliance with SEBI regulations.

19Mar 26

Lupin Announces Strategic Expansion of Dabhasa Manufacturing Facility in India

Lupin Manufacturing Solutions has announced a strategic expansion of its Dabhasa manufacturing facility in India, introducing two specialized peptide manufacturing units and enhanced infrastructure to boost development and manufacturing capabilities. The expansion aims to support growing global demand for complex pharmaceutical solutions, particularly peptides and biologic ADCs, reinforcing LMS's position in the global peptide ecosystem.

18Mar 26

Lupin Records ₹32.74 Crore Block Trade on NSE at ₹2,300.20 Per Share

Lupin Ltd. executed a significant block trade on NSE worth ₹32.74 crores, involving approximately 142,339 shares at ₹2,300.20 per share. The transaction highlights substantial institutional trading activity in the pharmaceutical company's stock and represents a notable block deal in the current market environment.